Breakwater Capital Group Sells 131 Shares of Danaher Co. (NYSE:DHR)

Breakwater Capital Group reduced its holdings in shares of Danaher Co. (NYSE:DHR) by 4.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,822 shares of the conglomerate’s stock after selling 131 shares during the quarter. Breakwater Capital Group’s holdings in Danaher were worth $648,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of DHR. Teachers Insurance & Annuity Association of America purchased a new position in Danaher in the third quarter worth about $39,000. MidAtlantic Capital Management Inc. purchased a new position in shares of Danaher in the third quarter worth approximately $40,000. FSA Wealth Management LLC purchased a new position in shares of Danaher in the third quarter worth approximately $50,000. Darwin Wealth Management LLC bought a new stake in Danaher during the third quarter valued at approximately $55,000. Finally, Modus Advisors LLC purchased a new stake in shares of Danaher in the 4th quarter worth $56,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Stock Performance

Shares of NYSE DHR opened at $239.83 on Tuesday. The stock has a fifty day moving average price of $235.52 and a two-hundred day moving average price of $253.65. Danaher Co. has a 1 year low of $222.53 and a 1 year high of $281.70. The firm has a market cap of $173.22 billion, a P/E ratio of 45.77, a PEG ratio of 4.32 and a beta of 0.83. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The business had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter last year, the firm posted $2.02 earnings per share. Danaher’s revenue was up 3.1% compared to the same quarter last year. Research analysts forecast that Danaher Co. will post 7.5 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be issued a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.45%. The ex-dividend date is Friday, December 27th. Danaher’s dividend payout ratio (DPR) is presently 20.61%.

Analysts Set New Price Targets

Several analysts recently issued reports on DHR shares. Raymond James cut their target price on Danaher from $310.00 to $300.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Guggenheim began coverage on shares of Danaher in a research report on Thursday, December 19th. They set a “buy” rating and a $275.00 target price on the stock. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, December 14th. UBS Group dropped their price target on shares of Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research note on Wednesday, October 23rd. Finally, Stifel Nicolaus raised their price target on Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research note on Wednesday, October 23rd. Six analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat, Danaher has a consensus rating of “Moderate Buy” and a consensus price target of $286.80.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.